Logistical feasibility and potential benefits of a population-wide passive immunotherapy program during an influenza pandemic.
作者信息
Wu Joseph T, Lee Cheuk Kwong, Cowling Benjamin J, Yuen Kwok Yung
机构信息
Department of Community Medicine and School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong KongSpecial Administrative Region, Hong Kong, China.
出版信息
Influenza Other Respir Viruses. 2011 May;5(Suppl 1):226-9.
Abstract
摘要
相似文献
1
Logistical feasibility and potential benefits of a population-wide passive immunotherapy program during an influenza pandemic.流感大流行期间全人群被动免疫治疗计划的后勤可行性和潜在益处。
Influenza Other Respir Viruses. 2011 May;5(Suppl 1):226-9.
2
Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic.在流感大流行期间开展全民被动免疫疗法计划的后勤可行性和潜在效益。
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3269-74. doi: 10.1073/pnas.0911596107. Epub 2010 Feb 1.
3
Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A(H1N1) MF59-adjuvanted vaccine.2009年甲型H1N1流感大流行期间，母体接种含MF59佐剂疫苗后经胎盘的抗体转移
JAMA. 2010 Dec 1;304(21):2360-1. doi: 10.1001/jama.2010.1729.
4
Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1.抗猪流感病毒抗体可中和甲型 H1N1 大流行流感病毒。
Mol Med Rep. 2011 Mar-Apr;4(2):209-14. doi: 10.3892/mmr.2011.410. Epub 2011 Jan 3.
5
Confronting the next pandemic--workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010.应对下一次大流行——大流行性流感（H1N1）2009 疫苗效力检测经验教训和未来效力检测工作研讨会，加拿大渥太华，2010 年 7 月 27 日至 29 日。
Influenza Other Respir Viruses. 2011 Nov;5(6):438-42. doi: 10.1111/j.1750-2659.2011.00250.x. Epub 2011 Apr 7.
6
Assessing seasonal vaccine-related cross-protection from 2009 pandemic H1N1 influenza through teacher absenteeism.通过教师缺勤情况评估季节性疫苗对2009年甲型H1N1流感大流行的相关交叉保护作用。
Aust N Z J Public Health. 2011 Aug;35(4):393-4. doi: 10.1111/j.1753-6405.2011.00748.x.
7
[Infectious diseases: progress in diagnosis and treatment. Topics: II. Measures to prevent the outbreaks; 1. Changes in medical care for influenza: before and after the H1N1 pandemic].[传染病：诊断与治疗进展。主题：二、预防疫情爆发的措施；1. 甲型H1N1流感大流行前后流感医疗护理的变化]
Nihon Naika Gakkai Zasshi. 2012 Nov 10;101(11):3114-22. doi: 10.2169/naika.101.3114.
8
Reflections on pandemic (H1N1) 2009 and the international response.对 2009 年甲型 H1N1 流感大流行和国际应对的反思。
PLoS Med. 2010 Oct 5;7(10):e1000346. doi: 10.1371/journal.pmed.1000346.
9
Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine.季节性流感感染和活疫苗可引发对 2009 年大流行 H1N1 疫苗的反应。
Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1140-5. doi: 10.1073/pnas.1009908108. Epub 2011 Jan 3.
10
Immunogenicity and safety of pandemic H1N1 2009 influenza vaccine for HIV-1 patients.2009年甲型H1N1流感疫苗对HIV-1患者的免疫原性和安全性
Acta Virol. 2012;56(4):349-51. doi: 10.4149/av_2012_04_349.
引用本文的文献
1
Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.使用异源多克隆抗体的益处以及对新型和治疗不足的传染性病原体的潜在应用。
Vaccine. 2016 Feb 24;34(9):1152-61. doi: 10.1016/j.vaccine.2016.01.016. Epub 2016 Jan 20.
2
An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.一种针对流感中和性绵羊多克隆抗体高效优化生产的经验方法表明，新型佐剂 CoVaccine HT™ 在功能上优于弗氏佐剂。
PLoS One. 2013 Jul 23;8(7):e68895. doi: 10.1371/journal.pone.0068895. Print 2013.
本文引用的文献
1
Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009.临床和病毒学参数对大流行性流感 A 病毒 H1N1 2009 中和抗体水平的影响。
Clin Infect Dis. 2010 Aug 1;51(3):274-9. doi: 10.1086/653940.
2
Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic.在流感大流行期间开展全民被动免疫疗法计划的后勤可行性和潜在效益。
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3269-74. doi: 10.1073/pnas.0911596107. Epub 2010 Feb 1.
3
The transmissibility and control of pandemic influenza A (H1N1) virus.大流行性流感 A（H1N1）病毒的传播和控制。
Science. 2009 Oct 30;326(5953):729-33. doi: 10.1126/science.1177373. Epub 2009 Sep 10.
4
Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.美国学童大流行和季节性流感疫苗接种策略。
Am J Epidemiol. 2009 Sep 15;170(6):679-86. doi: 10.1093/aje/kwp237. Epub 2009 Aug 13.
5
What is the optimal therapy for patients with H5N1 influenza?H5N1流感患者的最佳治疗方法是什么？
PLoS Med. 2009 Jun 23;6(6):e1000091. doi: 10.1371/journal.pmed.1000091.
6
Transmission potential of the new influenza A(H1N1) virus and its age-specificity in Japan.日本新型甲型H1N1流感病毒的传播潜力及其年龄特异性
Euro Surveill. 2009 Jun 4;14(22):19227. doi: 10.2807/ese.14.22.19227-en.
7
Pandemic potential of a strain of influenza A (H1N1): early findings.甲型H1N1流感病毒株的大流行潜力：早期发现。
Science. 2009 Jun 19;324(5934):1557-61. doi: 10.1126/science.1176062. Epub 2009 May 11.
8
Treatment with convalescent plasma for influenza A (H5N1) infection.用康复期血浆治疗甲型H5N1流感感染。
N Engl J Med. 2007 Oct 4;357(14):1450-1. doi: 10.1056/NEJMc070359.
9
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza.抗H5N1流感人源单克隆抗体的预防和治疗效果
PLoS Med. 2007 May;4(5):e178. doi: 10.1371/journal.pmed.0040178.
10
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?荟萃分析：用于西班牙流感肺炎的恢复期血液制品：未来治疗H5N1的方法？
Ann Intern Med. 2006 Oct 17;145(8):599-609. doi: 10.7326/0003-4819-145-8-200610170-00139. Epub 2006 Aug 29.
Zotero 插件